'Unique Oncology Platform': Gilead (GILD) Earns Two Upgrades After Beat-and-raise Quarter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Trump says Canada's Bombardier must build jets in US or lose market access
- European shares subdued as surging crude sharpens focus on ECB rate path
- Wall St slips as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Gilead Sciences (GILD) PT Raised to $86 at Jefferies
October 28, 2022 8:59 AM EDTJefferies analyst Michael Yee raised the price target on Gilead Sciences (NASDAQ: GILD) to $86.00 (from $78.00) while maintaining a Buy rating following results.
The analyst commented, "GILD put up a good Q across the board and esp strong Veklury Covid quarter... More
Gilead Sciences (GILD) PT Raised to $87 at JPMorgan
October 28, 2022 7:58 AM EDTJPMorgan analyst Chris Schott raised the price target on Gilead Sciences (NASDAQ: GILD) to $87.00 (from $80.00) while maintaining a Overweight rating.... More
Gilead Sciences (GILD) PT Raised to $75 at Wells Fargo
October 28, 2022 7:27 AM EDTWells Fargo analyst Mohit Bansal raised the price target on Gilead Sciences (NASDAQ: GILD) to $75.00 (from $74.00) while maintaining a Equal Weight rating.... More
Gilead Sciences (GILD) PT Raised to $82 at RBC Capital
October 28, 2022 6:13 AM EDTRBC Capital analyst Brian Abrahams raised the price target on Gilead Sciences (NASDAQ: GILD) to $82.00 (from $79.00) while maintaining a Outperform rating.... More
